Beijing Lepu Pharmaceutical Technology Co., Ltd.

Primary purpose: To study the absorption rate and extent of sildenafil citrate tablets (specification: 100 mg) developed by Lepu Pharmaceutical Co., Ltd., using sildenafil citrate tablets (trade name: Viagra®; specification: 100 mg) held by Pfizer Pharmaceuticals Co., Ltd. as the reference preparation in healthy subjects under fasting or postprandial conditions, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary purpose: To observe the safety of oral test preparations and reference preparations in healthy subjects.

Primary objective: To study the pharmacokinetics of empagliflozin metformin extended-release tablets (specifications: empagliflozin 5 mg/metformin hydrochloride 1000 mg) developed by Lepu Pharmaceutical Co., Ltd. under fasting and postprandial conditions in healthy subjects, using empagliflozin metformin extended-release tablets (trade name: SYNJARDY® XR; specifications: empagliflozin 5 mg/metformin hydrochloride 1000 mg) held by Boehringer Ingelheim Pharmaceuticals, Inc as the reference preparation, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation and the reference preparation in oral administration to healthy subjects.

Primary objective: To study the pharmacokinetics of ritonavir tablets (specification: 100 mg; test preparation) developed by Lepu Pharmaceutical Technology Co., Ltd. in healthy subjects in fasting and postprandial states, using ritonavir tablets (specification: 100 mg, trade name: NORVIR) as the reference preparation, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of oral test preparation and reference preparation in healthy subjects.